Skip to main content
SpringerLink
Log in

Clinical Trial Simulation in Drug Development

  • Commentary
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Clinical trial simulation is the application of old technologies, e.g., Monte Carlo simulation, to a newproblem, that problem being how to maximize the information content obtained during the drugdevelopment process with an intent to have the greatest chance of “success” in a clinical trial. When the informationcontent of the drug is high, then simulation provides a method to synthesize that information into acoherent package that indicates the sponsor has good control over the pharmacology of the drug. Froma purely financial point of view, what simulation offers pharmaceutical companies is the possibility ofreducing the number of required studies, maximizing the chances for success in a clinical trial, andpossibly shortening development time; all outcomes which will reduce drug development costs. Thepurpose of this paper is to introduce clinical trial simulation to the reader by discussing its potential indrug development, to briefly review the literature, and to make recommendations and caveats regardingits use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. S. C. D. Johnson. The role of simulation in the management of research: What can the pharmaceutical industry learn from the aerospace industry? Drug Info. J. 32:961-969 (1998).

    Google Scholar 

  2. J. Urquhart. Comparative regulation of drug and aircraft development: Lessons for regulatory reform? Clin. Pharmacol. Ther. 62:583-586 (1997).

    Google Scholar 

  3. Boston Consulting Group. (1993). Analysis of Pharmaceutical Manufacturers Association (PMA) data.

  4. C. Peck. (1999). Presented at the Best Practices Workshop in Clinical Trial Simulation, Arlington VA. Quoted in.

  5. I. Mahmood and J. D. Balian. The pharmacokinetic principles behind scaling from preclinical to Phase I protocols. Clin. Pharmacokin. 36:1-11 (1999).

    Google Scholar 

  6. J. D. Elashoff, G. G. Koch, and G. Y. Chi. Designing a clinical trial to demonstrate prevention of ulcer recurrents: modeling simulation approaches. Stat. Med. 7:877-888 (1988).

    Google Scholar 

  7. W. Barlow and S. Azen. The Silicone Study group: The effect of therapeutic treatment crossovers on the power of clinical trials. Contr. Clin. Trials 11:314-326 (1990).

    Google Scholar 

  8. T. A. Gooley, P. J. Martin, L. D. Fisher, and M. Pettinger. Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation. Contr. Clin. Trials 15:450-462 (1994).

    Google Scholar 

  9. M. M. Brooks, A. Hallstrom, and M. Peckova. A simulation study used to design the sequential monitoring plan for a clinical trial. Stat. Med. 14:2227-2237 (1995).

    Google Scholar 

  10. V. Schmith. (1995). Can population pharmacodynamics influence labeling? Three examples. Presented at the American Association of Pharmaceutical Scientists annual meeting.

  11. R. Gieschke, B. G. Reigner, and J.-L. Steimer. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modeling. Int. J. Clin. Pharmacol. Ther. 35:469-474 (1997).

    Google Scholar 

  12. M. D. Hale, A. J. Nicholls, R. E. S. Bullingham, R. Hene, A. Hoitsma, J.-P. Squifflet, W. Weimer, Y. Vanrenterghem, F. J. Van de Woude, and G. E. Verpooten. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin. Pharmacol. Ther. 64:672-683 (1998).

    Google Scholar 

  13. P. A. Lockwood, E. H. Cox, J. W. Mandema, J. R. Koup, W. Ewy, and R. J. Powell. (1999). Computer Assisted Trial Design (CATD) to support dose selection for CI-1008 in chronic neuropathic pain trials. Presented at Best Practices in Modeling and Simulation Workshop, Arlington, VA, Feb 1999.

  14. M. Gauthier: Clinical trial simulation. App. Clin. Trials 6:22-25 (1997).

    Google Scholar 

  15. R. Y. Rubinstein. Simulation and the Monte Carlo Method, John Wiley and Sons, Inc., New York, 1981.

    Google Scholar 

  16. M. Hale, W. R. Gillespie, S. Gupta, N. Tvk, N. Holford. Clinical trial simulation: Streamlining your drug development process. App. Clin. Trials 5:35-40 (1996).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Quintiles, Clinical Pharmacokinetics, PO Box 9708 (L4-M2828), Kansas City, Missouri, 64134

    Peter L. Bonate

Authors
  1. Peter L. Bonate
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonate, P.L. Clinical Trial Simulation in Drug Development. Pharm Res 17, 252–256 (2000). https://doi.org/10.1023/A:1007548719885

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007548719885

Search

Navigation